• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Apollo Endosurgery Inc. (Amendment)

    2/6/23 4:05:40 PM ET
    $APEN
    Industrial Specialties
    Health Care
    Get the next $APEN alert in real time by email
    SC 13G/A 1 apollo_13ga6.htm SC 13G/A
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G
     
    Under the Securities Exchange Act of 1934
     
    (Amendment No. 6)*
     
    Apollo Endosurgery, Inc.
    (Name of Issuer)
     
    Common Stock, $0.001 par value per share
    (Title of Class of Securities)
     
    03767D108
    (CUSIP Number)
     
    December 31, 2022
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    o Rule 13d-1(b)
    x Rule 13d-1(c)
    o Rule 13d-1(d)
       

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).  

     
     
    CUSIP No. 03767D108 13G Page 2 of 8

     

                 
    1.

    Names Of Reporting Persons

    I.R.S. Identification No. Of Above Persons (Entities Only)

     

    GAGNON SECURITIES LLC

     

     
           
    2. check the appropriate box if a group (a) o
    (b) x

    3. sec use only    
           
    4.

    citizenship or place of organization

     

    DELAWARE LIMITED LIABILITY COMPANY

     

       
    number of
    shares
    beneficially
    owned by
    each
    reporting
    person with:
    5. sole voting power     0
    6. shared voting power     1,824,331
    7. sole dispositive power     0
    8. shared dispositive power     1,962,770
    9. aggregate amount beneficially owned by each reporting person   1,962,770
    10. check box if the aggregate amount in row (9) excludes certain shares (See Instructions) o
    11. percent of class represented by amount in row (9)  

    4.7%

    12. type of reporting person (See Instructions)     IA, BD

     

     
     
     
    CUSIP No. 03767D108 13G Page 3 of 8

     

                 
    1.

    Names Of Reporting Persons

     

    GAGNON ADVISORS, LLC

     

     
           
    2. check the appropriate box if a group (a) o
    (b) x

    3. sec use only    
           
    4.

    citizenship or place of organization

     

    DELAWARE LIMITED LIABILITY COMPANY

     

       
    number of
    shares
    beneficially
    owned by
    each
    reporting
    person with:
    5. sole voting power     0
    6. shared voting power     1,329,354
    7. sole dispositive power     0
    8. shared dispositive power    

    1,329,354

    9. aggregate amount beneficially owned by each reporting person  

    1,329,354

    10. check box if the aggregate amount in row (9) excludes certain shares (See Instructions) o
    11. percent of class represented by amount in row (9)  

    3.2%

    12. type of reporting person (See Instructions)     IA

     

     
     
     
    CUSIP No. 03767D108 13G Page 4 of 8

     

                 
    1.

    Names Of Reporting Person

     

    NEIL GAGNON

     

     
           
    2. check the appropriate box if a group (a) o
    (b) x

    3. sec use only    
           
    4.

    citizenship or place of organization

     

    USA

     

       
    number of
    shares
    beneficially
    owned by
    each
    reporting
    person with:
    5. sole voting power    

    237,371

    6. shared voting power    

    3,340,918

    7. sole dispositive power    

    237,371

    8. shared dispositive power    

    3,493,520

    9. aggregate amount beneficially owned by each reporting person  

    3,730,891

    10. check box if the aggregate amount in row (9) excludes certain shares (See Instructions) o
    11. percent of class represented by amount in row (9)  

    9.0%

    12. type of reporting person (See Instructions)     IN

     

     
     
     
    CUSIP No. 03767D108 13G Page 5 of 8
    Item 1.  

     

    (a) Name of Issuer: Apollo Endosurgery, Inc.
         
    (b) Address of Issuer’s Principal

    1120 S. Capital of Texas Highway

      Executive Offices:

    Building 1, Suite #300
    Austin, Texas 78746

     

    Item 2.

    (a) Name of Person Filing:

    Neil Gagnon has sole voting and dispositive power over 237,371 shares of the Issuer’s Common Stock, $0.001 par value per share (the “common stock”). In addition, Mr. Gagnon has shared voting power over 3,340,918 shares of common stock and shared dispositive power over 3,493,520 shares of common stock.

     

    Mr. Gagnon is the managing member and principal owner of Gagnon Securities LLC (“GS”), an investment adviser registered with the U.S. Securities and Exchange Commission (“SEC”) under the Investment Advisers Act of 1940, as amended (the “Advisers Act”), and a registered broker-dealer, in its role as investment manager to several customer accounts, foundations, partnerships and trusts (collectively, the “Accounts”) to which it furnishes investment advice. GS and Mr. Gagnon may be deemed to share voting power with respect to 1,824,331 shares of common stock held in the Accounts and dispositive power with respect to 1,962,770 shares of common stock held in the Accounts. GS and Mr. Gagnon expressly disclaim beneficial ownership of all securities held in the Accounts.

     

    Mr. Gagnon is also the Chief Executive Officer of Gagnon Advisors, LLC (“Gagnon Advisors”), an investment adviser registered with the SEC under the Advisers Act. Mr. Gagnon and Gagnon Advisors, in its role as investment manager to Gagnon Investment Associates, LLC (“GIA”), a private investment fund, may be deemed to share voting and dispositive power with respect to 1,329,354 shares of common stock held by GIA. Gagnon Advisors and Mr. Gagnon expressly disclaim beneficial ownership of all securities held by GIA.

     

    (b) Address of Principal Business Office 1370 Ave. of the Americas, 24th Floor
      or, if none, Residence: New York, NY 10019

     

    (c) Citizenship:

    Gagnon Securities LLC

    Delaware limited liability company

       

    Gagnon Advisors, LLC

    Delaware limited liability company

       

    Neil Gagnon

    USA

         
    (d) Title of Class of Securities:

    Common Stock, $0.001 par value per share

         
    (e) CUSIP Number: 03767D108

     

     
     
     
    CUSIP No. 03767D108 13G Page 6 of 8
       
    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 13d-2(b) or (c), check whether the person filing is a:

     

    (a)  o Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
         
    (b)  o Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
         
    (c)  o Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
         
    (d)  o Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).
         
    (e)  o An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
         
    (f)  o An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
         
    (g)  o A parent holding company or control person in accordance with § 13d-1(b)(1)(ii)(G);
         
    (h)  o A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
         
    (i)  o A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15U.S.C. 80a-3);
         
    (j)  o A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
         
    (k)  o Group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

     

     
     
     
    CUSIP No. 03767D108 13G Page 7 of 8
    Item 4. Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a) Amount beneficially owned:

    Gagnon Securities LLC

    1,962,770

         

    Gagnon Advisors, LLC

    1,329,354

         

    Neil Gagnon

    3,730,891

           
      (b) Percent of class:

    Gagnon Securities LLC

    4.7%

         

    Gagnon Advisors, LLC

    3.2%

         

    Neil Gagnon

    9.0%

           
         

    Beneficial ownership information is reported as of December 31, 2022. Percentage amounts are based on 41,634,162 shares of common stock outstanding as of October 28, 2022, as disclosed in the Issuer’s Form 10-Q filed on November 1, 2022.

    The foregoing excludes shares of Common Stock issuable upon exercise of 6.0% Convertible Debentures due 2024 (the “Debentures”), because the Debentures contain a blocker provision pursuant to which they are convertible only to the extent that the number of shares of common stock issuable, together with the number of shares of common stock beneficially owned by the holder and its affiliates (excluding shares of common stock underlying unconverted or unexercised options, warrants or convertible securities, including unconverted Debentures, subject to an analogous limitation on exercise or conversion), would not exceed 9.99%.

           
      (c) Number of shares as to which the person has:

     

      (i) Sole power to vote or to direct the vote:

    Gagnon Securities LLC

    0

         

    Gagnon Advisors, LLC

    0
         

    Neil Gagnon

    237,371

           
      (ii) Shared power to vote or to direct the vote:

    Gagnon Securities LLC

    1,824,331

         

    Gagnon Advisors, LLC

    1,329,354

         

    Neil Gagnon

    3,340,918

           
      (iii) Sole power to dispose or to direct the disposition of:

    Gagnon Securities LLC

    0
         

    Gagnon Advisors, LLC

    0
         

    Neil Gagnon

    237,371

           
      (iv) Shared power to dispose or to direct the disposition of:

    Gagnon Securities LLC

    1,962,770

         

    Gagnon Advisors, LLC

    1,329,354

         

    Neil Gagnon

    3,493,520

    Item 5. Ownership of Five Percent or Less of a Class.
       

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    The Accounts described above in Item 2 have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, securities held in their respective accounts. To the knowledge of the Reporting Person, the interest in any such account does not exceed 5% of the class of securities. Except to the extent described herein, the Reporting Person disclaims beneficial ownership of all such securities.

     

    Items 7 – 9. Not Applicable.

     

     
     
     
    CUSIP No. 03767D108 13G Page 8 of 8
       
    Item 10. Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Section 230.14a-11.

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 6, 2023

       
    NEIL GAGNON
       
     

    /s/ Neil Gagnon

       
     

    GAGNON SECURITIES LLC

       
     

    /s/ Neil Gagnon

      Name:  Neil Gagnon 
     

    Title:    Managing Member

       
     

    GAGNON ADVISORS, LLC

       
     

    /s/ Neil Gagnon

      Name:  Neil Gagnon 
     

    Title:    Chief Executive Officer

       
     
     
    Get the next $APEN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $APEN

    DatePrice TargetRatingAnalyst
    1/4/2023$10.00Buy → Hold
    Stifel
    11/30/2022$14.00 → $10.00Buy → Hold
    Lake Street
    2/23/2022$12.00 → $10.00Buy
    Stifel
    12/15/2021$13.00Outperform
    Cowen & Co.
    12/9/2021$12.00Buy
    Stifel
    9/9/2021$15.00Overweight
    Stephens
    More analyst ratings

    $APEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Mcgaughy R Kent Jr

      4 - Apollo Endosurgery, Inc. (0001251769) (Issuer)

      4/4/23 8:15:52 PM ET
      $APEN
      Industrial Specialties
      Health Care
    • SEC Form 4 filed by Cpmg Inc

      4 - Apollo Endosurgery, Inc. (0001251769) (Issuer)

      4/4/23 8:13:25 PM ET
      $APEN
      Industrial Specialties
      Health Care
    • SEC Form 4 filed by Barr John R

      4 - Apollo Endosurgery, Inc. (0001251769) (Issuer)

      4/4/23 7:56:41 PM ET
      $APEN
      Industrial Specialties
      Health Care

    $APEN
    SEC Filings

    See more
    • SEC Form 15-12G filed by Apollo Endosurgery Inc.

      15-12G - Apollo Endosurgery, Inc. (0001251769) (Filer)

      4/14/23 10:24:35 AM ET
      $APEN
      Industrial Specialties
      Health Care
    • SEC Form EFFECT filed by Apollo Endosurgery Inc.

      EFFECT - Apollo Endosurgery, Inc. (0001251769) (Filer)

      4/10/23 12:15:09 AM ET
      $APEN
      Industrial Specialties
      Health Care
    • SEC Form EFFECT filed by Apollo Endosurgery Inc.

      EFFECT - Apollo Endosurgery, Inc. (0001251769) (Filer)

      4/10/23 12:15:16 AM ET
      $APEN
      Industrial Specialties
      Health Care

    $APEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Apollo Endosurgery downgraded by Stifel with a new price target

      Stifel downgraded Apollo Endosurgery from Buy to Hold and set a new price target of $10.00

      1/4/23 7:13:09 AM ET
      $APEN
      Industrial Specialties
      Health Care
    • Apollo Endosurgery downgraded by Lake Street with a new price target

      Lake Street downgraded Apollo Endosurgery from Buy to Hold and set a new price target of $10.00 from $14.00 previously

      11/30/22 9:24:28 AM ET
      $APEN
      Industrial Specialties
      Health Care
    • Stifel reiterated coverage on Apollo Endosurgery with a new price target

      Stifel reiterated coverage of Apollo Endosurgery with a rating of Buy and set a new price target of $10.00 from $12.00 previously

      2/23/22 8:47:05 AM ET
      $APEN
      Industrial Specialties
      Health Care

    $APEN
    Financials

    Live finance-specific insights

    See more
    • BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FOURTH QUARTER AND FULL YEAR 2022

      MARLBOROUGH, Mass., Feb. 1, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) generated net sales of $3.242 billion during the fourth quarter of 2022, growing 3.7 percent on a reported basis, 8.7 percent on an operational1 basis and 7.1 percent on an organic2 basis, all compared to the prior year period. Included within organic results is a negative approximately 200 basis point impact associated with unplanned reserves established for Italian government payback provisions3. The company reported GAAP net income available to common stockholders of $126 million or $0.09 per share (EPS), compared to $80 million or $0.06 per share a year ago and achieved adjusted4 EPS of $0.45 for th

      2/1/23 6:30:00 AM ET
      $APEN
      $BSX
      Industrial Specialties
      Health Care
      Medical/Dental Instruments
    • Apollo Endosurgery to Report Third Quarter Results on November 1, 2022

      AUSTIN, TX / ACCESSWIRE / October 18, 2022 / Apollo Endosurgery, Inc. ("Company" or "Apollo") (NASDAQ:APEN), a global leader in next-generation minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced that the Company is scheduled to release financial results for the third quarter ended September 30, 2022 on Tuesday, November 1, 2022, after market close.In conjunction with the release, Apollo will host a live webcast audio call with presentation slides at 3:30 p.m. CT / 4:30 p.m. ET to discuss the results. Investors are invited to join the live call via webcast from the Investors section of the Company's corporate website at www.apolloendo.com.An audi

      10/18/22 8:00:00 AM ET
      $APEN
      Industrial Specialties
      Health Care
    • Apollo Endosurgery to Report Second Quarter Results on August 2, 2022

      AUSTIN, TX / ACCESSWIRE / July 21, 2022 / Apollo Endosurgery, Inc. ("Company" or "Apollo") (NASDAQ:APEN), a global leader in next-generation minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced that the Company is scheduled to release financial results for the second quarter ended June 30, 2022 on Tuesday, August 2, 2022, after market close.In conjunction with the release, Apollo will host a live webcast audio call with presentation slides at 3:30 p.m. CT / 4:30 p.m. ET to discuss the results. Investors are invited to join the live call via webcast from the Investors section of the Company's corporate website at www.apolloendo.com.An audio-only op

      7/21/22 8:00:00 AM ET
      $APEN
      Industrial Specialties
      Health Care

    $APEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Apollo Endosurgery Inc. (Amendment)

      SC 13G/A - Apollo Endosurgery, Inc. (0001251769) (Subject)

      5/8/23 11:07:57 AM ET
      $APEN
      Industrial Specialties
      Health Care
    • SEC Form SC 13D/A filed by Apollo Endosurgery Inc. (Amendment)

      SC 13D/A - Apollo Endosurgery, Inc. (0001251769) (Subject)

      4/4/23 8:50:48 PM ET
      $APEN
      Industrial Specialties
      Health Care
    • SEC Form SC 13G filed by Apollo Endosurgery Inc.

      SC 13G - Apollo Endosurgery, Inc. (0001251769) (Subject)

      4/4/23 4:00:12 PM ET
      $APEN
      Industrial Specialties
      Health Care

    $APEN
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $APEN
    Leadership Updates

    Live Leadership Updates

    See more
    • BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FOURTH QUARTER AND FULL YEAR 2022

      MARLBOROUGH, Mass., Feb. 1, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) generated net sales of $3.242 billion during the fourth quarter of 2022, growing 3.7 percent on a reported basis, 8.7 percent on an operational1 basis and 7.1 percent on an organic2 basis, all compared to the prior year period. Included within organic results is a negative approximately 200 basis point impact associated with unplanned reserves established for Italian government payback provisions3. The company reported GAAP net income available to common stockholders of $126 million or $0.09 per share (EPS), compared to $80 million or $0.06 per share a year ago and achieved adjusted4 EPS of $0.45 for th

      2/1/23 6:30:00 AM ET
      $APEN
      $BSX
      Industrial Specialties
      Health Care
      Medical/Dental Instruments
    • Apollo Endosurgery Announces Two Important Milestones in the Advancement of Endoscopic Procedures for Patients Living with Obesity

      MERIT Trial Selected as 2022 Top Story in Gastroenterology and ASMBS adds Apollo Systems to List of Approved Bariatric DevicesAUSTIN, TX / ACCESSWIRE / December 13, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, announced today that the MERIT trial, published in The Lancet earlier this year(1), was selected as 2022 Top Story in Gastroenterology.(2) Additionally, the American Society for Metabolic and Bariatric Surgery (ASMBS) formally added four Apollo systems to its list of FDA Approved Bariatric Devices on December 5.(3) These milestones come only months after Apollo received FDA

      12/13/22 7:30:00 AM ET
      $APEN
      Industrial Specialties
      Health Care
    • Apollo Endosurgery to be Acquired by Boston Scientific

      Boston Scientific to acquire Apollo for $10.00 per share in cashAUSTIN, TX / ACCESSWIRE / November 29, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a leading minimally invasive medical device company for gastrointestinal and bariatric procedures, announced today it has entered into a definitive merger agreement to be acquired by Boston Scientific Corporation ("Boston Scientific"), a global medical technology leader, in an all-cash transaction with an enterprise value of approximately $615 million.[1] This transaction has been unanimously approved by the Apollo Board of Directors.The acquisition price of $10.00 per share represents an approximate 67% premium to the closing price

      11/29/22 7:00:00 AM ET
      $APEN
      Industrial Specialties
      Health Care
    • MIMEDX Announces Leadership Transition

      K. Todd Newton Appointed as Interim Chief Executive Officer, Replacing Timothy R. Wright, Effective Immediately MARIETTA, Ga., Sept. 06, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company"), a transformational placental biologics company, today announced that K. Todd Newton, a member of the MIMEDX Board of Directors, has been appointed interim Chief Executive Officer (CEO). Mr. Newton replaces Timothy R. Wright, who served as MIMEDX's CEO since May of 2019. M. Kathleen Behrens, Ph.D., Chairperson of MIMEDX's Board, said, "On behalf of the entire MIMEDX Board of Directors, I thank Tim for his contributions during an important time in MIMEDX's history and w

      9/6/22 7:00:00 AM ET
      $APEN
      $MDXG
      Industrial Specialties
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Apollo Endosurgery Appoints Jeannette Bankes to Board of Directors

      Veteran Brings 30 Years of Multinational Healthcare Leadership ExperienceAUSTIN, TX / ACCESSWIRE / April 4, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced the appointment of Jeannette Bankes to its Board of Directors, bringing the number of board members to eight. Bankes is the President and General Manager of the Global Surgical Franchise at Alcon, a worldwide developer, manufacturer and marketer of eye care medical devices and ophthalmic products."Jeannette Bankes is a seasoned healthcare executive and board member known for applying her tremendous insight, experi

      4/4/22 7:15:00 AM ET
      $APEN
      Industrial Specialties
      Health Care
    • Apollo Endosurgery Appoints Keely Scamperle as Vice President of Reimbursement and Market Access

      Veteran Leader Brings 25 Years of Global Medical Device ExperienceAUSTIN, TX / ACCESSWIRE / January 18, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced the hiring of Keely Scamperle as Vice President, Reimbursement & Market Access, effective January 17, 2022."At Apollo, we are addressing large unmet clinical needs in both gastroenterology and weight loss. We understand that developing products and procedures is only one component, and that facilitating patient access is a key element to successfully developing these markets," said Chas McKhann, president and CEO of A

      1/18/22 7:45:00 AM ET
      $APEN
      Industrial Specialties
      Health Care